Neurocrine Will Delay Ongentys Launch, But It Thinks Differentiation Is Clear
Executive Summary
Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.
You may also be interested in...
COVID-19 Still Dampens Neurocrine Revenues Despite Industry’s Q3 Uptick
The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.
Earnings Roundup: Specialty/Smaller Biopharmas See Modest Hit From Pandemic
First quarter financials and COVID-19 impacts from Bausch, Neurocrine, Theravance, Ironwood, Rigel.
Keeping Track Of US FDA Decisions: Approvals For Ongentys And New Keytruda, Darzalex Dosing, But Not For Trevyent
The latest US FDA approval decision news and highlights from the Pink Sheet’s FDA Performance Tracker